Hospitals | December 08, 2021
Yashoda Hospitals, Hyderabad saves five-year-old with timely kidney surgery
Approximately five kg tumor was removed in the eight-hour long complicated surgery
Approximately five kg tumor was removed in the eight-hour long complicated surgery
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
The interim data combines three mRNAs into one therapy injected directly into the tumour
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The recommendation is based on positive results from the pivotal Phase 3 CheckMate -649 trial in which Opdivo plus chemotherapy demonstrated superior overall survival versus chemotherapy
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
